Compare Incyte Corporation (INCY) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Tyson Foods, Inc. — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Tyson Foods, Inc. trades at $53.41 (market cap $18.41B). The key difference: Incyte Corporation is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Tyson Foods, Inc. for 76 Days on average.
| INCY | TSN | |
|---|---|---|
Market Cap | $22.85B | $18.41B |
Volume | 1,927,029 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $68.75 |
52-Week Low | $83.80 | $50.47 |
Typical Hold Time | 33 Days | 76 Days |
Enterprise Value | $18.35B | $25.68B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Tyson Foods (TSN) trades at $53.43, up 3.35% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99, beating expectations, but faces challenges with thin 1.03% net margins and ongoing beef segment losses. Recent news highlights securities investigations and reduced 2026 revenue guidance, creating investor uncertainty despite institutional buying activity.
The stock presents a cautious opportunity with analyst consensus target of $65.40 (22% upside) but faces significant headwinds from margin pressure and legal scrutiny. Key risks include beef segment profitability, potential securities violations, and volatile cash flow patterns. Upside depends on operational improvements and resolution of ongoing investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
